UK markets close in 6 hours 1 minute

Iovance Biotherapeutics, Inc. (0JDK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
16.25-10.79 (-39.89%)
As of 4:32PM BST. Market open.

Iovance Biotherapeutics, Inc.

999 Skyway Road
Suite 150
San Carlos, CA 94070
United States
650 260 7120
http://www.iovance.com

Sector(s)
Industry
Full-time employees241

Key executives

NameTitlePayExercisedYear born
Dr. Frederick G. Vogt Ph.D., Esq.Interim Pres, CEO, Gen. Counsel & Corp. Sec.515.4kN/A1974
Mr. Jean-Marc Bellemin M.B.A.Chief Financial Officer & Principal Accounting Officer580kN/A1972
Dr. Friedrich Graf Finckenstein M.D.Chief Medical Officer551.4kN/A1967
Dr. Igor P. BilinskyChief Operating OfficerN/AN/A1973
Ms. Sara PellegrinoVP of Investor Relations & PRN/AN/AN/A
Mr. Howard B. JohnsonSr. VP of Corp. Devel., Alliance Management & Program ManagementN/AN/A1960
James ZieglerSr. VP of CommercialN/AN/AN/A
Mr. Madan JagasiaSr. VP of Medical AffairsN/AN/AN/A
Dr. Elma S. HawkinsAdvisor to the BoardN/AN/A1957
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Corporate governance

Iovance Biotherapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.